compounding semaglutide fda Drugmakers and pharmacists battle over who gets to make obesity drugs Despite FDA ruling, compounded GLP-1s

The FDA approval of the first oral GLP-1 medication for obesity in December 2025 represents a major milestone in weight loss treatment options

Severe constipation unresponsive to interventions can be debilitating

Most users notice appetite changes first, then gradual weight changes over weeks to months, especially when dose increases are done slowly and side effects are managed

It stacks it on top of every other stressor in your life work pressure, family obligations, financial stress, poor sleep, and the baseline hormonal shifts that come with being over 40

If youre exploring which weight loss medication might be best for you, its important to understand the differences between them